A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.

Kensuke UsukiToshihiro MiyamotoTakuji YamauchiKiyoshi AndoYoshiaki OgawaMasahiro OnozawaTakahiro YamauchiHitoshi KiyoiAkira YokotaTakayuki IkezoeYuna KatsuokaSatoru TakadaNobuyuki AotsukaYasuyoshi MoritaTakayuki IshikawaNoboru AsadaShuichi OtaAtsushi DohiKensaku MorimotoShunji ImaiUmi KishimotoKoichi AkashiYasushi Miyazakinull null

Published in: International journal of hematology (2024)

NS-87/CPX-351 can be considered as a frontline treatment option for Japanese patients with high-risk AML.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
dengue virus
randomized controlled trial
combination therapy
zika virus
low dose
replacement therapy